6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction

The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:

• i a 5-substituted pyrazolo [4,3-d]pyrimdine-7-one as disclosed in European patent application 0201188;
• ii a griseolic acid derivative as disclosed in European patent applications nos 0214708 and 0319050;
• iii a 2-phenylpurinone derivative as disclosed in European patent application 0293063;
• iv a phenylpyridone derivative as disclosed in European patent application 0347027;
• v a fused pyrimidine derivative as disclosed in European patent application 0347146;
• vi a condensed pyrimidine derivative as disclosed in European patent application 0349239;
• vii a pyrimidopyrimidine derivative as disclosed in European patent application 0351058;
• viii a purine compound as disclosed in European patent application 0352960;
• ix a quinazolinone derivative as disclosed in European patent application 0371731;
• x a phenylpyrimidone derivative as disclosed in European patent application 0395328;
• xi an imidazoquinoxalinone derivative or its aza analogue as disclosed in European patent application 0400583;
• xii a phenylpyrimidone derivative as disclosed in European patent application 0400799;
• xiii a phenylpyridone derivative as disclosed in European patent application 0428268;
• xiv a pyrimidopyrimidine derivative as disclosed in European patent 0442204;
• xv a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
• xvi a 4,5-dihydro-4-oxo-pyrrolo[1,2-a]quinoxaline derivative or its aza analogue as disclosed in European patent application 0584487;
• xvii a polycyclic guanine derivative as disclosed in International patent application WO91/19717;
• xviii a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
• xix a 2-benzyl-polycyclic guanine derivative as disclosed in International patent application WO94/19351;
• xx a quinazoline derivative as disclosed in U.S. Pat. No. 4,060,615
• xxi a 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one as disclosed in U.S. Pat. No. 5,294,612
• xxii a benzimidazole as disclosed in Japanese patent application 5-222000;
• or
• xxiii a cycloheptimidazole as disclosed in European Journal of Pharmacology, 251, (1994),1.
• xxiv a N-containing heterocycle as disclosed in International patent application WO94/22855.